ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / NRIX / dividends
VRDN (45) BHC (68) TLX (47) IDYA (34) ⌘ Pro Terminal β†’

Nurix Therapeutics Inc. (NRIX) Dividend Safety Gauge & 10-Year DRIP Compounder

$25.70 -4.10% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.46

Nurix Therapeutics Inc. (NRIX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $2.93B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRIX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Nurix Therapeutics Inc. (NASDAQ: NRIX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $25.70 (-4.10% 1D, market cap $2.93B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRIX ranks #324 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NRIX compare to VRDN and BHC in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRIX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRIX?
β–Ό

Per NRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0001549595), Nurix Therapeutics Inc. generated $84.0M in revenue (+54.0% YoY), -$264.5M in net income, and -$263.5M in free cash flow against $688.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $25.46 (-0.93%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (46/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510046
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D Β· Rk D
Cash (8)Whales (17)SEC (11)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$30 Bull$24 Base$19 Bear
πŸ“¬ FREE NRIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NRIX)Realized 20D OHLCV Swing Band: Β±10.6%
Deterministic 5-Pillar Attribution (46/100 Composite)
πŸ” WHY NRIX SCORES 46/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+17/20 pts (37% of score)

20D Institutional Volume Accumulation (Β±10.6% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (24% of score)

Altman Z-Score 9.52 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$22.13+17.9% Next Q
Q2 (-2Q)
41
Grade D$26.10+2.3% Next Q
Q3 (-1Q)
43
Grade D$26.70-3.7% Next Q
Current
46
Grade D$25.70-6.1% Hist 90D Ξ±
Trajectory: E (38) β†’ D (46)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NRIX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NRIX currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.00) and Max Pain ($26.99) forces dealer call-delta covering toward $29.64.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRIXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNRIX Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $40,809

Est. Year-10 Shareholder Yield: $245/yr
$11.5K
Yr 1
$13.2K
Yr 2
$15.2K
Yr 3
$17.6K
Yr 4
$20.2K
Yr 5
$23.3K
Yr 6
$26.8K
Yr 7
$30.8K
Yr 8
$35.5K
Yr 9
$40.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRIX)

  • βœ“Walkthrough of NRIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NRIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.80%πŸ“ HORIZONTAL RANGE
2026-11-03O $27.12H $27.12L $25.70C $25.70VOL 2.31M
RES: $27.98SUP: $21.23SMA50: $25.00SMA200: $20.26
$29.22$25.13$21.03$16.94$12.85RES $27.98SUP $21.23$25.702026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NRIX Butterfly Map β†’ + Track NRIX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +54.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRIX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NRIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NRIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRIX)

Health Care Rank #324 of 1015 βš”οΈ VRDN vs NRIX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NRIX vs. VRDN, BHC, TLX, IDYA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nurix Therapeutics Inc. (NRIX) ranks #324 by composite RQD confidence (46/100, grade D) and #208 by equity capitalization ($2.93B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and β€” gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with NRIX at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NRIX ACTIVE
Nurix Therapeutics Inc.
D 46/100 β€” β€” -35.0% -4.10% $2.93B Benchmark Subject
VRDN
Viridian Therapeutics Inc.
D 45/100 β€” β€” -35.0% +2.55% $2.79B /vrdn-vs-nrix β†’
BHC
Bausch Health Companies Inc.
C+ 68/100 21.2x β€” 7.6% -2.19% $3.07B /bhc-vs-nrix β†’
TLX
Telix Pharmaceuticals Limited
D 47/100 β€” β€” β€” -0.55% $3.08B /tlx-vs-nrix β†’
IDYA
IDEAYA Biosciences Inc.
E 34/100 β€” β€” -13.8% -1.00% $3.08B /idya-vs-nrix β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-11-30 β€’ CIK 0001549595 β†—

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Nurix Therapeutics Inc. (NRIX) reported GAAP revenue of $84.0M (+54.0% vs. FY2024 revenue of $54.5M , and +9.1% cumulative change since FY2023) , GAAP net income of -$264.5M, operating cash flow of -$249.5M, and free cash flow of -$263.5M (-44.9% YoY). On the balance sheet, NRIX closed FY2025 with $688.1M in total assets against $0 in total debt (Altman Z-Score: 9.52, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-11-30 $84.0M -$264.5M -$249.5M -$263.5M $688.1M β€”
FY2024 (FY) 2024-11-30 $54.5M -$193.6M -$172.6M -$181.9M $669.3M β€”
FY2023 (FY) 2023-11-30 $77.0M -$143.9M -$81.4M -$81.4M β€” β€”

3. NRIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nurix Therapeutics Inc. (NASDAQ: NRIX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $25.70 (-4.10% 1D, market cap $2.93B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRIX ranks #324 in composite RQD confidence.

How does NRIX compare to VRDN and BHC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRIX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.79B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRIX?

Per NRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0001549595), Nurix Therapeutics Inc. generated $84.0M in revenue (+54.0% YoY), -$264.5M in net income, and -$263.5M in free cash flow against $688.1M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRIX trading relative to its 50-day, 200-day, and 52-week technical levels?

NRIX last traded at $25.70 (-4.10% on volume of 2,348,566 shares), positioning the stock +2.80% above its 50-day simple moving average ($25.00) and +26.85% above its 200-day simple moving average ($20.26). Across its 52-week range of $11.67 to $28.23, NRIX sits at the 84.7% percentile with a 14-day RSI of 62.3 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.6% ($22.98 to $28.42).

Direct Sub-Reports: NRIX RQD Cockpit NRIX 12M Forecast NRIX Earnings & Move NRIX Dividends & DRIP NRIX Insiders & 13F NRIX Whale Options NRIX Profit Sankey NRIX News & Why
ROARABLE RATING BRIEF β€’ RQD 46/100 (D) βœ“ SEC XBRL & RQD VERIFIED

NRIX β€” Nurix Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-11-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nurix Therapeutics Inc. (NRIX) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $25.70 (-4.10% 1D, market capitalization $2.93B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of -8.89%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.52, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nurix Therapeutics Inc. Is listed on NASDAQ under the ticker NRIX.. The company reported revenue of $84.0M for FY 2025, indicating some revenue generation alongside operating losses.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-11-30), Nurix Therapeutics Inc. (NRIX) reported $84.0M in annual revenue (up from $54.5M in FY2024, +54.0% YoY) and -$264.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($77.0M revenue, -$143.9M net income) through FY2025, NRIX scaled operating cash flow to -$249.5M and free cash flow to -$263.5M, backed by $688.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 46/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -8.89% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $11.67 – $28.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream supply-chain links, no sector correlations, and no proprietary signals recorded. The source data therefore does not identify upstream suppliers, downstream customers, or 2nd-order bottlenecks. Investors should note that this absence reflects the data provided, not a confirmed absence of dependencies.

  • Key Question #1: Can NRIX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $84.0M and free cash flow of -$263.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NRIX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nurix Therapeutics Inc. (NRIX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NRIX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRIX Bull vs. Bear Conversation Board β€” What's Your Call at $25.70?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRIX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NRIX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $34.30 (+28.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 17/20 in the RQD rating, and cash rose to $247.0M in FY 2025 from $110.0M in F

Picked up a starter position in NRIX in my $100K Virtual Cash book at $26.80. Institutional accumulation and options positioning score 17/20 in the RQD rating, and cash rose to $247.0M in FY 2025 from $110.0M in FY 2024.. Trading inside a $11.67–$28.23 52-week range with -8.89% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader πŸ‚ BULL

@MultipleCompression Shorting a 17/20 institutional whale-flow stock at $26.80 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $21.44 (-20.0%)
Spot @ $26.80

Valuation & margin reality check on NRIX at $26.80 before chasing here

Fading this rally in NRIX at $26.80. Valuation & margin reality check on NRIX at $26.80 before chasing here. With a beta of 1.0 and the stock sitting at $26.80 (52-wk range $11.67–$28.23), the easy multiple expansion is already priced in.

LIVE TAPE